<DOC>
	<DOCNO>NCT02778282</DOCNO>
	<brief_summary>The goal MySafeRx study evaluate feasibility , acceptability , usability novel platform integrate text message reminder , secure electronic pill organizer , daily remote brief motivational recovery support visit standardize protocol supervise self- administration buprenorphine via videoconferencing .</brief_summary>
	<brief_title>MySafeRx™ : An Integrated Mobile Platform Buprenorphine Adherence</brief_title>
	<detailed_description>Opioid use disorder serious public health issue . Buprenorphine/ Naloxone ( B/N ) partial opioid mu-receptor agonist dose daily prevents opioid withdrawal , block opioid euphoria prevent opioid overdose . Extended treatment B/N increase rate abstinence outpatient treatment retention decrease Hepatitis C ( HCV ) transmission . B/N treatment dropout associate relapse overdose death . B/N adherence may critical factor influence retention reduce overall healthcare cost . Also , B/N diversion associate poor adherence become increasingly common worrisome . While many patient achieve stability start B/N treatment , 80 % 18-25 year old leave treatment within year relapse common reason . Ongoing illicit opioid use treatment increase odds relapse dropout . The MySafeRx™ platform help prescribers offer high level support vulnerable patient opioid use disorder period clinical instability . The MySafeRx™ platform combination several key component , include daily videoconferencing check-ins motivational interviewing-based recovery coaching , text-messaging reminder , secure storage B/N medication within secure electronic pill dispenser , standardize protocol supervise self-administration medication via videoconferencing . By offer recovery support medication adherence monitor program period instability , system could improve treatment outcomes ensure increase adherence , also prevent B/N diversion . This study primarily seek demonstrate feasibility MySafeRx™ platform among young adult ( 18-34 year , inclusive ) opioid use disorder . While key component may individual therapeutic effect , hypothesize integrated process involve key component may necessary unlock full therapeutic potential mobile platform daily remote supervise self-administration diversion prevention among group . Providing targeted motivational interviewing recovery support context-specific moment daily medication-taking people receptive treatment may offer new opportunity expand recovery support deliver .</detailed_description>
	<mesh_term>Buprenorphine</mesh_term>
	<criteria>1 . Women men age 1834 , inclusive , competent , wish participate willing provide inform consent . 2 . DSMV diagnosis opioid use disorder , moderate severe 3 . Seeking initiate buprenorphine treatment currently receive buprenorphine treatment recent positive illicit opioid urine toxicology miss schedule urine toxicology . 1 . DSMV diagnosis dementia , neurodegenerative disease , organic mental disorder , mental retardation , autism . 2 . Substantial cognitive impairment ( Montreal Cognitive Assessment &lt; 25/30 ) 3 . Currently homeless 4 . Actively homicidal suicidal imminent plan 5 . Serious unstable medical illness include , cardiovascular , hepatic , renal , respiratory , endocrine , neurological , hematological disease hospitalization treatment illness likely within next 3 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>34 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>